軟部肉腫に対する化学療法における悪心・嘔吐の制御

Prevention of Chemotherapy-induced Nausea and Vomiting in Soft Tissue Sarcoma Patients

　背景：軟部肉腫に対する化学療法による悪心・嘔吐(CINV)の制御に関して，ニューキノロン1受容体拮抗薬(アプレピタント)とセロトニン5-HT₃(5-HT)受容体拮抗薬(グラニセトロン，パロノセトロン)の有効性を比較検討した．

　対象と方法：対象は，軟部肉腫で化学療法を行った18例である．

　結果：CINVに対してパロノセトロンとアプレピタント併用投与やグラニセトロンとアプレピタント併用投与が，グラニセトロン単独と比較し有効性が高かった．

　まとめ：CINVの制御により，入院期間の短縮や患者の化学療法への意識の向上・継続性に有用となることが期待される．

　Background：The purpose of this study was to evaluate the efficacy of the 5-hydroxytryptamine receptor antagonists granisetron and palonosetron and the neurokinin-1 receptor antagonist aprepitant in preventing chemotherapy-induced nausea and vomiting (CINV) in soft tissue sarcoma patients.

　Methods：The subjects were 18 patients who were receiving chemotherapy for soft tissue sarcoma.

　Outcome：Combination therapy with palonosetron and aprepitant and combination therapy with granisetron and aprepitant were significantly more effective than treatment with granisetron alone in preventing CINV.

　Conclusion：Control of CINV was useful in shortening length of hospital stay and in improving patients' continued acceptance of chemotherapy.